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EphB2 Promotes Progression of Cutaneous Squamous
Cell Carcinoma
Mehdi Farshchian1,2, Liisa Nissinen1,2, Elina Siljamäki1,3, Pilvi Riihilä1,2, Mervi Toriseva4, Atte Kivisaari1,2,
Risto Ala-aho1,2, Markku Kallajoki5, Esko Veräjänkorva6, Hanne-Kaisa Honkanen7, Ritva Heljasvaara7,
Taina Pihlajaniemi7, Reidar Grénman8, Juha Peltonen4, Sirkku Peltonen1 and Veli-Matti Kähäri1,2
Keratinocyte-derived skin cancer, cutaneous squamous cell carcinoma (cSCC), is the most common metastatic
skin cancer. We have examined the role of Eph/ephrin signaling in the progression of cSCC. Analysis of the
expression of EPH and EFN families in cSCC cells and normal epidermal keratinocytes revealed overexpression of
EPHB2 mRNA in cSCC cells and cSCC tumors in vivo. Tumor cell–speciﬁc overexpression of EphB2 was detected
in human cSCCs and in chemically induced mouse cSCCs with immunohistochemistry, whereas the expression
of EphB2 was low in premalignant lesions and normal skin. Knockdown of EphB2 expression in cSCC
cells suppressed growth and vascularization of cSCC xenografts in vivo and inhibited proliferation, migration,
and invasion of cSCC cells in culture. EphB2 knockdown downregulated expression of genes associated
with biofunctions cell viability, migration of tumor cells, and invasion of tumor cells. Among the genes
most downregulated by EphB2 knockdown were MMP1 and MMP13. Moreover, activation of EphB2 signaling by
ephrin-B2-Fc enhanced production of invasion proteinases matrix metalloproteinase-13 (MMP13) and MMP1,
and invasion of cSCC cells. These ﬁndings provide mechanistic evidence for the role of EphB2 in the
early progression of cSCC to the invasive stage and identify EphB2 as a putative therapeutic target in this invasive
skin cancer.
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INTRODUCTION
Cutaneous squamous cell carcinoma (cSCC) is a keratinocyte-
derived invasive and metastatic malignant tumor of skin
(Madan et al., 2010). The incidence of cSCC is increasing
worldwide, making it the most common form of metastatic
skin cancer (Rogers et al., 2010). Important risk factors
for cSCC include solar UV radiation, chronic ulcers, and
immunosuppression (Alam and Ratner, 2001). Primary cSCCs
have a tendency for recurrence and metastasis, and treatment
of metastatic cSCCs is challenging in the absence of targeted
therapies (Rowe et al., 1992; Czarnecki et al., 2002).
UV-induced inactivation of both alleles for tumor protein 53
(TP53) gene is an early event in keratinocyte carcinogenesis
resulting in marked expansion in simple mutations, making
cSCCs one of the human cancers with highest mutation rate
(Durinck et al., 2011; Ratushny et al., 2012). Another early
event in the progression of cSCC is loss-of-function mutation
of NOTCH1 (Wang et al., 2011; South et al., 2014). However,
at present, the knowledge on the molecular basis of cSCC
progression from premalignant lesion (actinic keratosis (AK))
to cSCC in situ (cSCCIS) and eventually to invasive cSCC
is incomplete (Ratushny et al., 2012). Therefore, molecular
markers for rapid progression and metastatic capacity of
cSCCs, as well as new therapeutic targets for these tumors, are
in need (Kivisaari and Kähäri, 2013).
Erythropoietin-producing hepatocellular (Eph) receptors
represent the largest family of receptor tyrosine kinases (RTKs)
(Pasquale, 2010). According to their structures and ligand-
binding afﬁnities, the human Eph RTKs and their ligands,
ephrins, are divided into subclasses A and B (Pasquale, 2010;
Nikolov et al., 2013). Glycosylphosphatidylinositol-linked
ephrin-A ligands (5 members) promiscuously bind to the
EphA RTKs (9 members) and transmembrane ephrin-B ligands
ORIGINAL ARTICLE
1Department of Dermatology, University of Turku and Turku University
Hospital, Turku, Finland; 2MediCity Research Laboratory, University of Turku,
Turku, Finland; 3Turku Centre for Biotechnology, University of Turku and Åbo
Akademi University, Turku, Finland; 4Department of Cell Biology and Anatomy,
University of Turku, Turku, Finland; 5Department of Pathology, University of
Turku and Turku University Hospital, Turku, Finland; 6Department of Plastic
and General Surgery, University of Turku and Turku University Hospital, Turku,
Finland; 7Biocenter Oulu and Faculty of Biochemistry and Molecular Medicine,
University of Oulu, Oulu, Finland and 8Department of Otorhinolaryngology,
Head and Neck Surgery, University of Turku and Turku University Hospital,
Turku, Finland
Correspondence: Veli-Matti Kähäri, Department of Dermatology, University of
Turku and Turku University Hospital, POB 52, Turku FI-20521, Finland.
E-mail: veli-matti.kahari@utu.ﬁ
Received 4 November 2014; revised 3 March 2015; accepted 4 March 2015;
accepted article preview online 19 March 2015; published online 9 April 2015
Abbreviations: AK, actinic keratosis; cSCC, cutaneous squamous cell
carcinoma; cSCCIS, cSCC in situ; Eph, erythropoietin-producing
hepatocellular; IHC, immunohistochemistry; MMP, matrix metalloproteinase;
NHEK, normal human epidermal keratinocyte; qRT-PCR, quantitative real-
time reverse-transcriptase–PCR; RTK, receptor tyrosine kinase; SCID, severe
combined immunodeﬁcient; siRNA, small interfering RNA
1882 Journal of Investigative Dermatology (2015), Volume 135 © 2015 The Society for Investigative Dermatology
(3 members) bind to EphB RTKs (5 members). As both receptor
and ligand are located on the cell surface, cell–cell contact is
usually needed for their interaction. Upon binding, both
receptors and ligands can activate cellular signaling resulting
in bidirectional reverse and forward signaling in adjacent cells
(Pasquale, 2010; Nikolov et al., 2013). In addition, there is
evidence for ligand-independent clustering and activation of
Eph RTKs on cell surface (Nikolov et al., 2013). The role of
Eph/ephrin signaling in numerous biological processes has
been established (Lin et al., 2010, 2012; Nievergall et al.,
2012; Gordon et al., 2013) and their role in skin homeostasis
has been well documented (Egawa et al., 2009; Lin et al.,
2010). In human epidermal keratinocytes, EphB2 acting as a
ligand triggers reverse signaling, and consequently promotes
epidermal differentiation (Walsh and Blumenberg, 2012). The
role of Eph/ephrin signaling in tumor progression in general
appears complex (Pasquale, 2010; Nievergall et al., 2012).
Knowledge available on their role in the progression of skin
cancer indicates that members of EphA subfamily serve as
tumor suppressors in epidermal keratinocytes, and that loss of
EphA2 enhances formation of chemically induced skin cancer
in mouse model (Guo et al., 2006b). Furthermore,
downregulation of EphA1 expression has been documented
in human nonmelanoma skin cancer (Hafner et al., 2006). At
present, the role of other members of Eph family in skin
cancer is unclear.
Here, we provide evidence that EphB2 plays a role in the
progression of cSCC. EphB2 is speciﬁcally overexpressed by
tumor cells in cSCCs and EphB2 promotes proliferation,
migration, and invasion of cSCC cells and growth of cSCC
in vivo by regulating the expression of genes associated with
cell migration and invasion. These results provide molecular
background for the role of EphB2 in cSCC progression and
identify EphB2 as a potential therapeutic target in this invasive
cancer of skin.
RESULTS
Overexpression of EPHB2 in cSCC cells and tumors
Expression of the entire EPH receptor and EFN ligand families
in primary (n= 5) and metastatic (n= 3) cSCC cell lines and
normal human epidermal keratinocytes (NHEKs) from 5
individuals was analyzed using microarray technique. Sig-
niﬁcant upregulation of EPHA4 and EPHB2 mRNA was noted
in cSCC cells as compared with NHEKs (Figure 1a). Moreover,
EFNB1 mRNA levels were signiﬁcantly lower in cSCC cell
lines than in NHEKs. Expression levels of EPH and EFN
mRNAs in cSCC cell lines and NHEKs were also determined
by next-generation sequencing. This analysis conﬁrmed
speciﬁc upregulation of EPHB2 mRNA and downregulation
of EFNB1 mRNA in cSCC cells as compared with NHEKs
(Figure 1b).
The expression proﬁling analyses with Affymetrix and RNA
sequencing identiﬁed EPHB2 as the only Eph receptor
signiﬁcantly overexpressed in cSCC cells with negligible
expression in NHEKs (Figure 1a and b). In addition, high
expression of EFNB2, which codes for ephrin-B2, a high-
afﬁnity ligand for EphB2, was detected in cSCC cells (Figure
1a and b). Therefore, EPHB2 and EFNB2 mRNA levels in
cSCC cell lines and NHEKs were determined with quantitative
real-time reverse-transcriptase–PCR (qRT-PCR). The results
showed signiﬁcant upregulation of EPHB2 mRNA in cSCC
cells, whereas the expression was very low in NHEKs
(Figure 1c). In contrast, abundant EFNB2 mRNA expression
was detected in both cSCC cells and NHEKs (Figure 1c). Next,
EPHB2 mRNA levels in cSCC tumors (n= 6) and normal skin
samples (n= 7) in vivo were determined with qRT-PCR. The
mean level of EPHB2 mRNA expression was signiﬁcantly
higher in cSCC tumors compared with normal skin
(Figure 1d). Abundant expression of EFNB2 mRNA was
detected in both cSCCs and normal skin (Figure 1d).
Overexpression of EphB2 on cSCC cell surface
Level of EphB2 production by NHEK and cSCC cell lines was
determined by western blot analysis of the total cell lysate.
Speciﬁc bands corresponding to EphB2 were detected in all
cSCC cell lines, whereas EphB2 protein level was very low in
NHEKs (Figure 1e). The levels of EphB2 on the surface of
cSCC cells and NHEKs were determined by western blot
analysis of the biotinylated cell surface proteins pulled down
with avidin. Speciﬁc EphB2 bands were detected on cell
surface in all cSCC cell lines examined, but not in NHEKs
(Figure 1f). Cell surface EphB2 and ephrin-B2 on cSCC cells
and NHEKs was also analyzed with immunoﬂuorescence
staining. Clustering of EphB2 was observed on the surface of
individual cSCC cells and in cell–cell contact sites between
adjacent cSCC cells (Figure 1g). Prominent staining for ephrin-
B2 was noted on the surface of cSCC cells colocalizing with
EphB2 clusters. In contrast, no labeling for EphB2 was
detected on the surface of NHEKs and staining for ephrin-
B2 on NHEKs was not clustered (Figure 1g).
Overexpression of EphB2 by tumor cells in human cSCCs in vivo
To study the role of EphB2 in the progression of cSCC
in vivo, tissue microarrays consisting of normal skin (n= 12),
UV-induced premalignant lesions (AK; n= 69), cSCCIS
(n=56), and cSCCs (n= 68) were analyzed by immunohis-
tochemistry (IHC) using anti-EphB2 antibody. Positive EphB2
staining was observed on cell surface (Figure 2a) or in
cytoplasm (Figure 2b and c) of tumor cells in invasive cSCCs
and cSCCIS (Figure 2f) and the intensity of EphB2 labeling was
in general stronger in cSCCs and cSCCIS than in premalignant
lesions (Figure 2e) and normal skin (Figure 2d).
Semiquantitative analysis of EphB2 stainings (Figure 2g)
revealed that the epidermal layer in normal skin (Figure 2d)
was negative in 58% and weakly positive (+) in 42% of
samples. In AK lesions (Figure 2e), EphB2 staining was mainly
negative (48%) or weakly positive (+) (49%). Stronger EphB2
labeling was observed in cSCCIS tissue samples, as moderate
(++) staining was observed in 19% of cSCCIS cases
(Figure 2f). In invasive cSCCs, strong (+++) (Figure 2c) and
moderate (++) (Figure 2b) tumor cell–associated EphB2
staining was noted in 24% of the tumors. In general, EphB2
staining was signiﬁcantly stronger in cSCCIS and cSCCs than
in normal skin and AK compared as groups (Figure 2g).
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Overexpression of EphB2 by tumor cells in chemically induced
mouse cSCCs
To obtain further evidence for the role of EphB2 in cSCC
progression in vivo, we employed the well-characterized
model of chemically induced mouse skin carcinogenesis
(Abel et al., 2009). Tissue samples from untreated normal
mouse skin (n= 5), vehicle-treated skin (n= 2), hyperplastic
mouse skin (n=6), and mouse cSCCs (n= 19) were stained for
EphB2 by IHC and semiquantitative analysis was performed
based on staining intensity. Strong (+++) (Figure 3b and c) or
moderate (++) (Figure 3a) EphB2 staining was noted in tumor
cells in nearly all mouse cSCCs studied (95% of cases) and
none of the tumors were negative. The majority of untreated
(Figure 3d) and vehicle-treated (Figure 3e) mouse skin tissues
were negative for EphB2 (86%) and weak (+) staining was
noted in the epidermal layer of only 14% of samples. In
hyperplastic mouse epidermal layer induced by 12-O-
tetradecanoyl phorbol-13-acetate treatment, weak (+) staining
for EphB2 (Figure 3f) was noted in 83% of cases and 17%
were negative. Signiﬁcantly stronger EphB2 staining was
detected in cSCC tumors compared with all nonmalignant
mouse skin tissues as a group (Figure 3g).
Alteration of gene expression proﬁle in cSCC cells after EphB2
knockdown
To elucidate the molecular basis of the role of EphB2 in cSCC
progression, microarray-based global gene expression proﬁl-
ing and pathway analysis were performed after small
interfering RNA (siRNA) knockdown of EphB2 expression in
cSCC cell lines (n= 3; Figure 4a). Analysis of the genes
signiﬁcantly regulated after EphB2 knockdown revealed that
the differentially expressed genes were signiﬁcantly asso-
ciated with the biofunction categories cell death, cellular
movement, cell-to-cell signaling and interactions, and cellular
growth and proliferation (Figure 4b). Interestingly, based on
the regulation z-score, cell viability, invasion of tumor cells,
migration of tumor cells,migration of cells, and cell movement
were the top biofunctions signiﬁcantly downregulated follow-
ing EphB2 knockdown (Figure 4b).
Analysis of the molecular network in the top biofunction
invasion of tumor cells revealed downregulation of mRNAs for
several matrix metalloproteinases (MMPs), especially MMP1
(collagenase-1) and MMP13 (collagenase-3) (Supplementary
Figure S1 online). Interestingly, out of 2,460 differentially
regulated probe sets, MMP1 and MMP13 were among the
most downregulated genes after EphB2 knockdown
(Figure 4c). In addition, comparison of the expression of the
entire MMP family revealed that the expression of MMP1 and
MMP13 was signiﬁcantly downregulated following EphB2
knockdown (Figure 4d). MMP1 and MMP13 were also
involved in other signiﬁcantly downregulated biofunctions
migration of tumor cells (Supplementary Figure S2 online),
migration of cells, cell movement, and cell viability (data
not shown).
EphB2 knockdown inhibits proliferation, migration, and
invasion of cSCC cells
To explore the functional role of EphB2 in cSCC cells (n= 3),
cell viability, cell migration, and invasion assays were
performed following EphB2 knockdown. A signiﬁcant reduc-
tion in the number of viable cSCC cells was noted 24, 48, and
72 hours after EphB2 knockdown (Figure 5a). Cell migration
assay was performed 48 hours after transfection of the cSCC
cells with control or EphB2 siRNA. Whereas the scratch
wounds healed completely within 24 hours in the cSCC cell
cultures transfected with control siRNA, knockdown of EphB2
expression clearly inhibited the motility of the cSCC cells
(Figure 5b and c). Analysis of cSCC cell migration with time-
lapse microscopy revealed effective and rapid migration of
cSCC cells transfected with control siRNA (Supplementary
Video S1 online). In contrast, a severe defect in the directional
migration of cSCC cells was noted following EphB2 knock-
down (Supplementary Video S2 online).
In addition, cSCC cells displayed signiﬁcantly reduced
invasion through collagen following knockdown of EphB2 as
compared with the control siRNA-transfected cSCC cells
(Figure 5d). EphB2 knockdown potently inhibited production
of MMP1 and MMP13 in cSCC cell line with high basal
expression level of MMP1 and MMP13 (Figure 5e). Further-
more, activation of EphB2 signaling by soluble EphB2 ligand,
ephrin-B2-Fc (Figure 5f), enhanced invasion of cSCC cells
through collagen (Figure 5g) and stimulated production of
MMP13 (Figure 5h) and MMP1 (Supplementary Figure S3
online).
EphB2 knockdown suppresses growth of human cSCC
xenografts
The role of EphB2 in cSCC growth in vivo was examined in
xenograft model established with cSCC cells implanted
subcutaneously in the back of severe combined immunodeﬁ-
cient (SCID) mice 72 hours after knockdown of EphB2 by
transfection with siRNA. A signiﬁcant delay in the growth of
tumors established with EphB2 siRNA-transfected cells was
noted already 4 days after implantation of the tumor cells as
compared with the control siRNA group, and the difference
Figure 1. Overexpression of EPHB2 in cutaneous squamous cell carcinoma (cSCC). (a) Microarray and (b) next-generation sequencing-based analysis of the
expression of EPH and EFN families in primary (Prim., n= 5) and metastatic (Met., n= 3) human cSCC cell lines and in primary normal human epidermal
keratinocytes (NHEKs; n= 5 or n= 4, respectively). (c) EPHB2 and EFNB2 mRNA levels in the same cSCC cell lines and NHEKs were determined by quantitative
real-time reverse-transcriptase–PCR (qRT-PCR). (d) EPHB2 and EFNB2 mRNA levels in cSCC tumors (n= 6) and normal human skin (n=7) in vivo were
determined by qRT-PCR. (e) EphB2 expression level was analyzed in cell lysates of NHEKs and cSCC cells. (f) Level of EphB2 protein on the cell surface of NHEKs
and cSCC cells was determined with western blot analysis of biotinylated cell surface proteins. (g) EphB2 and ephrin-B2 on the cell surface of the cSCC cells and
NHEKs were immunolabeled with primary and ﬂuorescently label secondary antibodies. Yellow signal shows colocalization of the EphB2 and ephrin-B2. Scale
bar=10 μm. *Po0.05, **Po0.01, ***Po0.001, NS, not signiﬁcant; Mann–Whitney two-way U-test.
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increased throughout the observation period of 28 days
(Figure 6a). Extended incubation of cSCC cells transfected
with siRNA showed persistence of EphB2 knockdown up to
8 days (data not shown).
Histological analysis of the xenografts harvested at day 28
revealed that the tumors established with EphB2 siRNA-
transfected cSCC cells contained more inert material and
were less cellular as compared with the xenografts in the
control siRNA group (Figure 6b, upper panels). Accordingly,
the relative number of proliferating (Ki-67-positive) tumor
cells was signiﬁcantly lower in the xenografts established with
cSCC cells transfected with EphB2 siRNA (17%) compared
with control siRNA tumors (39%) (Figure 6b, middle panels,
and Figure 6c). In addition, IHC analysis of the xenografts for
vascular marker CD34 revealed signiﬁcantly reduced density
of CD34-positive blood vessels in EphB2 knockdown tumors
compared with control siRNA xenografts (Figure 6b, lower
panels, and Figure 6d).
DISCUSSION
The role of Eph/ephrin signaling in normal biological
functions such as axon guidance, neural development, and
cell migration and adhesion is well established, but their role
in cancer progression is complex (Merlos-Suarez and Batlle,
2008; Coulthard et al., 2012). Distinct members of Eph/ephrin
families have emerged both as tumor suppressors and as
promoters of cancer progression (Merlos-Suarez and Batlle,
2008; Pasquale, 2010; Nievergall et al., 2012). Upregulation
of EphA2 expression has been documented in prostate
cancer (Walker-Daniels et al., 1999), breast cancer (Zelinski
et al., 2001), melanoma (Udayakumar et al., 2011), and
glioblastoma (Wykosky and Debinski, 2008), providing
evidence for its role in tumor progression. Furthermore,
EphB2 displays both tumor-suppressing and tumor-promoting
effects. EphB receptor activation suppresses growth of color-
ectal cancer (Batlle et al., 2005). Loss-of-function mutations or
deletion of EPHB2 have been reported in prostate cancer
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(Huusko et al., 2004), colorectal cancer (Alazzouzi et al.,
2005), and gastric cancer (Davalos et al., 2007). Reduction in
the expression of EphB2 is associated with invasion,
metastasis, and poor prognosis in colorectal tumors (Lugli
et al., 2005; Guo et al., 2006a), and high level of EphB2
expression in colorectal cancer is associated with longer
survival (Jubb et al., 2005). In contrast, activation of EphB2
has been shown to promote invasion of glioblastoma in vivo
(Wang et al., 2012). In transitional cell carcinoma of the
bladder, loss of EphB2 and gain of EphB4 expression have
been reported to be associated with the tumor progression,
and EphB4 inhibitors have been shown to have antitumor
properties in xenograft model of this tumor (Li et al., 2014).
Previous studies on the role of Eph/ephrin signaling in the
progression of skin cancer have identiﬁed members of EphA
subfamily, especially EphA2, as tumor suppressor in
epidermal keratinocytes (Guo et al., 2006b).
Here, we have examined the role of EphB2 in the
progression of cSCC, the most common metastatic skin
cancer (Alam and Ratner, 2001; Czarnecki et al., 2002;
Madan et al., 2010; Rogers et al., 2010). Overexpression of
EPHB2 was noted in primary and metastatic cSCC cell lines
compared with NHEKs using microarray and next-generation
sequencing techniques and qRT-PCR. Remarkably more
EphB2 was noted on the cell surface of cSCC cells as
compared with NHEKs with western blot analysis of cell
surface proteins and with immunoﬂuorescence staining.
Immunoﬂuorescence staining also revealed clustering of
EphB2 and colocalization with its ligand, ephrin-B2, on cSCC
cell surface. Moreover, analysis of EPHB2 mRNA levels by
qRT-PCR revealed signiﬁcant overexpression of EPHB2 in
cSCC tumors in vivo as compared with normal skin. In
addition, IHC analysis of a large panel of tissue samples from
normal skin, premalignant lesions (AKs), and cSCCs revealed
stronger tumor cell–associated labeling for ephB2 in cSCCIS
and cSCCs than in normal skin and AK lesions. Prominent
tumor cell–associated staining for EphB2 was also detected in
chemically induced murine skin SCCs, whereas the EphB2
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Figure 3. Overexpression of EphB2 in chemically induced mouse cutaneous squamous cell carcinoma (cSCC). (a–f) EphB2 expression was analyzed by
immunohistochemistry (IHC) of normal (n=5), vehicle-treated (n= 2), 12-O-tetradecanoyl phorbol-13-acetate (TPA)–treated mouse skin (n=6), and chemically
7,12-dimethylbenz[α]anthracene (DMBA)/TPA–induced mouse skin SCCs (n=19). (a) Moderate (++) and (b and c) strong (+++)cytoplasmic staining for EphB2
was detected in DMBA/TPA-induced mouse skin SCC. (f) Treatment of mouse skin with TPA-induced hyperplasia of the epidermis and a weak (+) EphB2 staining
of keratinocytes. EphB2 staining was mainly negative (− ) in epidermal layer of (d) untreated or (e) vehicle (acetone)-treated mouse skin. (g) Staining for EphB2
was signiﬁcantly more abundant in DMBA/TPA-induced mouse cSCCs compared with nonmalignant samples as a group. Scale bar=100 μm. ***Po0.001;
Fisher’s exact test.
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staining in hyperplastic and normal mouse skin was either
weak or absent. Similar to what has been observed in other
tumor cells (Wu et al., 2004), labeling for EphB2 was noted
predominantly in the cytoplasm of the cSCC tumor cells.
Internalization of the full-length EphB2 by endocytosis upon
activation is the possible explanation for the cytoplasmic
localization of EphB2 in vivo (Zimmer et al., 2003; Pasquale,
2010) Altogether, these results show that the expression of
EphB2 is very low in normal intact skin and is speciﬁcally
induced in tumor cells in cSCCs, suggesting EphB2 as a
biomarker for cSCC. Furthermore, expression of EphB2 in
cSCCIS provides evidence that the induction of EphB2
expression is an early event in cSCC development and
may play a role in the progression of in situ cSCC to the
invasive stage.
Knockdown of EphB2 expression in cSCC cells resulted in
signiﬁcant delay in the growth of cSCC xenograft tumors in
SCID mice already at the early stage compared with control
siRNA group. These results provide further evidence that
EphB2 plays a role in implantation and early growth of cSCC
tumor cells in vivo. Furthermore, our results showed that
EphB2 knockdown inhibited vascularization of the cSCC
xenografts, suggesting a role for EphB2 in cSCC tumor
angiogenesis. Functional studies with cSCC cells indicated
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Figure 4. Alteration of gene expression proﬁle in cutaneous squamous cell carcinoma (cSCC) cells after EphB2 knockdown. (a) UT-SCC12A cells were
transfected with EphB2 or control small interfering RNA (siRNA) and transfection efﬁciency was veriﬁed by western blotting. (b) Summary of signiﬁcantly regulated
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that knockdown of EphB2 expression markedly inhibited
proliferation and migration of cSCC cells. In addition, analysis
of cell migration by time-lapse microscopy showed that
knockdown of EphB2 potently inhibited directional migration
of cSCC cells. Eph signaling can mediate cell contact–
dependent cell repulsion that can guide directional migration
of cells (Poliakov et al., 2004; Lin et al., 2008). Our results
suggest that reduction in cell repulsion as a result of EphB2
knockdown leads to defective directional migration of cSCC
cells and may this way impair their invasion capacity.
The molecular background for the role of EphB2 in cSCC
growth and migration and invasion was examined by global
gene expression proﬁling of cSCC cells following EphB2
knockdown. Pathway analysis showed that signiﬁcantly
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downregulated genes were associated with biofunctions cell
viability, migration of cells, cell movement, migration of tumor
cells, and invasion of tumor cells. Among the genes most
downregulated by EphB2 knockdown wereMMP1 andMMP13
that code for collagenase-1 and collagenase-3, respectively, the
two metalloproteinases that are associated with cancer invasion.
Among these, MMP13 has previously been identiﬁed as an SCC-
speciﬁc proteinase, as it is expressed by tumor cells in SCCs of
the skin and head and neck, but not by keratinocytes in normal
skin and oral mucosa (Airola et al., 1997; Johansson et al.,
1997). MMP13 also promotes invasion of cSCC cells and growth
of cSCC in vivo (Ala-aho et al., 2004), and its expression in head
and neck SCCs correlates with local invasion (Stokes et al.,
2010). Our results showed that EphB2 knockdown potently
inhibited the production of MMP13 and MMP1 by cSCC cells,
resulting in inhibition of cSCC cell invasion through collagen.
On the other hand, activation of EphB2 with soluble ligand
ephrin-B2-Fc induced the expression of MMP13 and MMP1,
and increased cSCC cell invasion through collagen. Together,
these observations show that EphB2 speciﬁcally regulates the
expression of two important invasion proteinases, MMP13 and
MMP1, and may this way promote cSCC cell invasion and
implantation into tissue. Interestingly, both MMP13 and MMP1
can cleave ephrin-A1 and in this way regulate its signaling
function (Beauchamp et al., 2012) that may play a role in cSCC
progression (Hafner et al., 2006; Guo et al., 2006b).
In conclusion, our ﬁndings demonstrate speciﬁc over-
expression of EphB2 by cSCC cells in culture and in vivo.
These results identify EphB2 as a biomarker for cSCC and
propose a role for EphB2 in the early stage of tumor
progression to invasive cSCC. In addition, knockdown of
EphB2 expression suppresses growth of cSCC tumors in vivo
and inhibits proliferation, migration, and invasion of cSCC
cells. Altogether, these results suggest EphB2 as a therapeutic
target in cSCCs, especially in patients with unresectable,
recurrent, or multiple tumors, and in patients with high risk for
cSCC (e.g., immunosuppressed patients).
MATERIALS AND METHODS
Ethical issues
Approval for the use of archival tissue specimens and the collection
of normal skin and cSCC tissues was obtained from the Ethics
Committee of the Hospital District of Southwest Finland, Turku,
Finland. The study was performed in accordance with the Declara-
tion of Helsinki Principles. Each patient gave their informed written
consent. The experiments with mice were approved by the State
Provincial Ofﬁce of Southern Finland and conducted according to
institutional guidelines.
Cell culture
Human cSCC cell lines (n= 8) were established from surgically
removed cSCCs (Farshchian et al., 2011). NHEK cultures were
established from normal skin of patients (n= 10) undergoing surgery
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Figure 6. EphB2 knockdown suppresses growth of human cutaneous squamous cell carcinoma (cSCC) xenografts. (a) UT-SCC7 cells (5×106) were injected
subcutaneously into the back of severe combined immunodeﬁcient (SCID) mice 72 hours after transfection with EphB2 siRNA (n=8) or control siRNA (CsiRNA;
n= 7) (mean± SEM). (b) Tumors were harvested at day 28 and stained with hematoxylin and eosin (HE; upper panels), for proliferation marker Ki-67 (middle
panels), and for vascular endothelial marker CD34 (lower panels). Arrows indicate CD34-positive blood vessels. (c) The percentages of Ki-67-positive tumor cells
in xenografts were counted (mean± SEM). (d) The density of CD34-positive blood vessels in xenografts was analyzed (mean± SEM). Scale bar=100 μm.
*Po0.05, **Po0.01; Student’s t-test.
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for mammoplasty (Farshchian et al., 2011) and purchased from
PromoCell (n= 1) (Heidelberg, Germany). cSCC cells and NHEKs
were cultured as previously described (Farshchian et al., 2011;
Riihilä et al., 2014b).
Biochemical and molecular biology techniques
Protocols for gene expression proﬁling, qRT-PCR, western blot
analysis, analysis of cell surface protein, immunoﬂuorescence
staining, and analysis of phosphorylated EphB2 are provided in
Supplementary Materials and Methods online.
Tissue samples
Cutaneous SCC tumor samples (n= 6) were obtained from the Turku
University Hospital after surgery of primary tumors. Normal skin
samples (n= 7) were collected from the mammoplasty surgery
(Farshchian et al., 2011). Tissue microarray blocks consisting of
samples from normal sun-protected skin (n= 12), AK (n= 69), cSCCIS
(n= 56), and UV-induced cSCC (n= 68) were generated from the
archival parafﬁn blocks from the Department of Pathology, Turku
University Hospital (Farshchian et al., 2011; Riihilä et al., 2014b).
Mouse skin chemical carcinogenesis
Tissue sections of normal mouse skin (n= 5), acetone-treated (n= 2),
12-O-tetradecanoyl phorbol-13-acetate–treated hyperplastic skin
(n= 6), and 7,12-dimethylbenz[α]anthracene/12-O-tetradecanoyl
phorbol-13-acetate–induced mouse skin SCC (n= 19) were prepared
from the skin of FVB/N HanHsd mice as described previously
(Brideau et al., 2007; Farshchian et al., 2011).
Immunohistochemistry
Detailed protocol for IHC staining and analysis are given in
Supplementary Materials and Methods online.
EphB2 knockdown and functional studies
The detailed protocols for EphB2 knockdown with siRNA, cell
viability, migration and invasion assay, and MMP1 and MMP13
production analysis are described in the Supplementary Materials
and Methods online.
Human cSCC xenografts
SCID female, 6-week-old mice (CB17/Icr-Prkdcscid/IcrIcoCrl) (Charles
River Laboratories, Wilmington, MA) were randomly allocated into
EphB2 (n= 8) and control siRNA group (n= 7). UT-SCC7 cells
(5× 106) were injected subcutaneously into the back of mice 72
hours after the transfection with EphB2 or control siRNA (Ala-aho
et al., 2004). Tumors were measured and their volumes were
calculated using the formula: V= π4/3((L+W)/4) (Riihilä et al., 2014a).
Tumors were excised after 28 days, embedded in parafﬁn, and
stained with hematoxylin and eosin. Proliferating cells were detected
with IHC using mouse anti-Ki-67 antibody (Dako, Glostrup, Den-
mark). The percentages of Ki-67-positive cells were counted in four
distinct microscopic ﬁelds at × 20 magniﬁcation in areas with the
highest proportion of Ki-67 staining. Vascularization of the xenograft
tumors was assessed by IHC with anti-CD34 antibody (Santa Cruz
Biotechnology, Santa Cruz, CA). Blood vessel density was evaluated
in each sample by counting the number of CD34-positive blood
vessels in four deﬁned microscopic ﬁelds at × 20 magniﬁcation.
Statistical analysis
Statistical analysis between groups was performed with Mann-
Whitney U-test and Student’s t-test. Statistical analysis of the IHC
results was performed with Fisher’s exact test.
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